Dermatology
| Psoriasis
Dermatology
Psoriasis
Bimekizumab for the treatment of moderate to severe plaque psoriasis with scalp, nail and palmoplantar involvement through 52 weeks: post-hoc analysis from the BE VIVID phase 3 trial
book_2
Source:
EADV Virtual - Poster session
calendar_today
Published on Medfyle:
November 2020
headphones
3
min
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- Bimekizumab is a monoclonal IgG1 antibody that inhibits IL-17F and IL-17A.
- Post hoc analysis of subsets of patients with scalp, nail or palmoplantar psoriasis in the BE VIVID trial showed high levels of efficacy in these difficult to treat areas.
- At Week 16, more patients achieved a scalp PGA of 0 with bimekizumab than ustekinumab or placebo.
- Initial responses were maintained over 52 weeks in scalp and palmoplantar disease.
Presenting Author
Read more
arrow_downward
Hide
arrow_upward
Kim A. Papp, MD
Probity Medical Research and K Papp Clinical Research, Waterloo. Ontario, Canada